Cipla receives warning letter from USFDA for its Goa manufacturing facility

Cipla has received a warning letter from United States Food and Drug Administration (USFDA) for its Goa manufacturing facility. The USFDA inspected the facility from 16-27 September 2019. The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Powered by Capital Market - Live News